References:
1. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis. GASTROENTEROLOGY 2017;152(4):745-61.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424.
3. Jiang Y, Han QJ, Zhang J. Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol 2019;25(25):3151-67.
4. Kim DW, Talati C, Kim R. Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy. J Gastrointest Oncol 2017;8(2):256-65.
5. Hou J, Zhang H, Sun B, Karin M. The Immunobiology of Hepatocellular Carcinoma in Humans and Mice: Basic Concepts and Therapeutic Implications. J HEPATOL 2019.
6. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. NAT IMMUNOL 2013;14(10):1014-22.
7. Makarova-Rusher OV, Medina-Echeverz J, Duffy AG, Greten TF. The yin and yang of evasion and immune activation in HCC. J HEPATOL 2015;62(6):1420-9.
8. Chaturvedi V, Collison LW, Guy CS, Workman CJ, Vignali DA. Cutting edge: Human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J IMMUNOL 2011;186(12):6661-6.
9. Xue W, Yan D, Kan Q. Interleukin-35 as an Emerging Player in Tumor Microenvironment. J CANCER 2019;10(9):2074-82.
10. Fu YP, Yi Y, Cai XY, et al. . Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection. Br J Cancer 2016;114(7):767-76.
11. Zhang MX, Gan W, Jing CY, et al. . Overexpression of interleukin-35 in intrahepatic cholangiocarcinoma is a prognostic indicator after curative resection. CANCER SCI 2018;109(4):1195-206.
12. Wei X, Zhang J, Gu Q, Huang M, Zhang W, Guo J, Zhou X. Reciprocal Expression of IL-35 and IL-10 Defines Two Distinct Effector Treg Subsets that Are Required for Maintenance of Immune Tolerance. CELL REP 2017;21(7):1853-69.
13. Sawant DV, Yano H, Chikina M, et al. . Adaptive plasticity of IL-10(+) and IL-35(+) Treg cells cooperatively promotes tumor T cell exhaustion. NAT IMMUNOL 2019;20(6):724-35.
14. Shi YY, Dai MJ, Wu GP, Zhou PP, Fang Y, Yan XB. Levels of interleukin-35 and its relationship with regulatory T-cells in chronic hepatitis B patients. VIRAL IMMUNOL 2015;28(2):93-100.
15. Luo M, Peng H, Chen P, Zhou Y. The immunomodulatory role of interleukin-35 in fibrotic diseases. Expert Rev Clin Immunol 2019;15(4):431-9.
16. Shi M, Wei J, Dong J, Meng W, Ma J, Wang T, Wang N, Wang Y. Function of interleukin-17 and -35 in the blood of patients with hepatitis B-related liver cirrhosis. MOL MED REP 2015;11(1):121-6.
17. Zheng XF, Hu XY, Ma B, et al. . Interleukin-35 Attenuates D-Galactosamine/Lipopolysaccharide-Induced Liver Injury via Enhancing Interleukin-10 Production in Kupffer Cells. FRONT PHARMACOL 2018;9:959.
18. Wang W, Guo H, Li H, Yan Y, Wu C, Wang X, He X, Zhao N. Interleukin-35 Gene-Modified Mesenchymal Stem Cells Protect Concanavalin A-Induced Fulminant Hepatitis by Decreasing the Interferon Gamma Level. HUM GENE THER 2018;29(2):234-41.
19. Trehanpati N, Vyas AK. Immune Regulation by T Regulatory Cells in Hepatitis B Virus-Related Inflammation and Cancer. SCAND J IMMUNOL 2017;85(3):175-81.
20. Zhao N, Li H, Yan Y, Jiang R, He X. Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4(+) T cell function. CELL IMMUNOL 2017;312:61-6.
21. Yang L, Shao X, Jia S, Zhang Q, Jin Z. Interleukin-35 Dampens CD8(+) T Cells Activity in Patients With Non-viral Hepatitis-Related Hepatocellular Carcinoma. FRONT IMMUNOL 2019;10:1032.
22. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. CELL 2015;160(1-2):48-61.